Approved HIV Drugs
Approved HIV Drugs
HIV Treatment Highlights from IAS 2013 [VIDEO]
- Details
- Category: HIV Treatment
- Published on Sunday, 07 July 2013 00:00
- Written by Gregory Fowler
Cal Cohen offers a summary of some of the major studies of antiretroviral treatment strategies presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) last week in Kuala Lumpur.
IAS 2013: Switch to Etravirine Maintains Viral Suppression and Improves Lipid Levels
- Details
- Category: HIV Treatment
- Published on Saturday, 06 July 2013 00:00
- Written by Liz Highleyman
People with HIV who switch from their current antiretroviral regimen to the NNRTI etravirine (Intelence) maintain undetectable viral load and may see improvement in metabolic parameters, according to a report presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.
IAS 2013: Study Supports WHO Second-line HIV Treatment Guidelines for Resource-limited Countries
- Details
- Category: HIV Treatment
- Published on Wednesday, 03 July 2013 00:00
- Written by Liz Highleyman
A second-line regimen consisting of a protease inhibitor (PI) plus 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) led to good outcomes for people with HIV in Africa after initial regimen failure, according to data from the EARNEST study presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur. A NRTI-sparing regimen with raltegravir did not work significantly better, and PImonotherapy was inferior.
IAS 2013: First-line Antiretroviral Therapy has Improved Over Time, Meta-analysis Shows
- Details
- Category: HIV Treatment
- Published on Thursday, 04 July 2013 00:00
- Written by Liz Highleyman
The effectiveness of initial antiretroviral treatment has improved markedly over the years, but many people still do not achieve full HIV suppression and a majority end up going off their initial regimen for various reasons, according to a large meta-analysis presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.
GRACE Survey Sheds Light on Treatment Benefits and Barriers for HIV+ Women
- Details
- Category: Approved HIV Drugs
- Published on Thursday, 06 June 2013 00:00
- Written by Janssen
Caring for children, unemployment, and transportation difficulties were among the factors most likely to lead to poor adherence, early dropout, and suboptimal response to antiretroviral therapy (ART) among participants in the GRACE trial, which tested darunavir (Prezista) in a study population consisting largely of women of color. Overall, they said participation was a positive experience and they would encourage others to join a clinical trial.
More Articles...
- Efavirenz More Effective than Nevirapine for Children with HIV
- FDA Approves Efavirenz (Sustiva) for HIV+ Children Ages 3 Months to 3 Years
- Atripla Label Adds Drug Interactions with Hepatitis C Protease Inhibitors Boceprevir and Telaprevir
- CROI 2013: Second-line NRTI-sparing HIV Regimen Proves Equally Effective
Web Design and Development by